drugset / Trial / NCT01524016

68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia

NCT01524016

Phase 0 Unknown 100 enrolled Peking Union Medical College Hospital
NaSingle-groupOpen-labelDiagnostic

Summary

Oncogenic osteomalacia is rare disease predominantly caused by a small, somatostatin receptor positive mesenchymal tumor, which is frequently hidden in an unusual anatomical site and often goes undetected by conventional imaging. A permanent cure of the disease relies on exactly localizing the tumor and completely removing it. 68Ga-DOTATATE PET/CT is a novel scan that might have improved sensitivity and resolution specifically for somatostatin receptor positive tumors. The investigators will scan the suspicious and confirmed patients of oncogenic osteomalacia and compare it to 99mTc-HYNIC-TOC SPECT/CT and 18F-FDG PET/CT to see if it improves patient care.

Timeline

Start
2011-12
Primary completion
2017-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-DOTATATE Diagnostic / imaging agent 72 mbq Intravenous
Subject 68Ga-DOTATATE Diagnostic / imaging agent 185 mbq Intravenous